Analysis of Clinical featuRes and Echocardiographic Characteristics for Diagnosis of Infiltrative cardiomyopaThy (ACREDIT): Retrospective Multi-center Observational Study

This study sought to develop an algorithm by collecting echocardiographic image information and related clinical information capable of quantitatively evaluating changes of the myocardium through machine learning. Moreover, the researchers investigate the usefulness of an algorithm for early diagnosis and differential diagnosis of infiltrative cardiomyopathy.

Study Overview

• Status: Recruiting
• Conditions: Infiltrative Cardiomyopathy

Detailed Description

1. Study Design: Multicenter Retrospective Observational Study
2. Study method: If the above selection criteria are met, the index visit echocardiographic images which were performed immediately before or closest to the time of hospitalization for final diagnosis, echocardiographic images of the pre-visit and post-visit from the final diagnosis, and clinical information will be obtained. Chest X-ray, electrocardiogram, and echocardiography images are extracted in raw DICOM format and then analyzed in the core lab (Severance hospital). The characteristics of patients with infiltrative cardiomyopathy are identified through the collection of relevant clinical information, and a method for non-invasive early diagnosis and differential diagnosis of infiltrative cardiomyopathy is developed.

3. Quantative analysis of echocardiographic images using Radiomics

   • Radiomics is a method of extracting a large number of quantitative image features (300-500 features such as shape, entropy, volume, etc.) from non-invasive medical images (CT, MRI, etc.) and statistically analyzing the features. Its value has been demonstrated through the studies for prediction of breast cancer recurrence and lesion classification.
   • Using the open source platform PyRadiomics19, we extract the radiomic characteristics for brightness (Energy, Entropy, Mean, Median, etc.) and texture (Gray Level Co-occurrence Matrix Contrast, Difference Variance, Maximal Correlation Coefficient, etc.) from the set region of interest.
   • The differences between infiltrative cardiomyopathy and normal control are identified using clinical information and radiomics features extracted from echocardiography at the time of the diagnosis visit. The algorithms to distinguish the disease will be developed using machine learning methods such as support vector machine classifier.

• Study Type: Observational
• Enrollment (Anticipated): 500

Contacts and Locations

• Study Contact: Name: Hyuk-jae Chang; Phone Number: +82 2-2228-8460; Email: hjchang@yuhs.ac

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • Recruiting
    • Yonsei University Health System, Severance Hospital, Division of Cardiology
    • Contact: Hyuk-jae Chang; Phone Number: +82 2-2228-8460; Email: hjchang@yuhs.ac

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

It is important to obtain as large image data as possible to develop an algorithm capable of diagnosing various infiltrative myocardial diseases.

Infiltrative cardiomyopathy is a rare disease, and it was reported that the prevalence of cardiac amyloidosis in Korea was 1.91 per 100,000 in 2015.2 In the case of other diseases, there has been no report of the prevalence in Korea, but reports from an overseas report that cardiac sarcoidosis is 2.2 per 100,000, 8 and Fabry disease is 0.9 to 2.5 per 100,000. 9,10 Securing enough data that can be learned to improve machine learning accuracy is not easy because of the scarcity of invasive cardiomyopathy. Furthermore, it is difficult to confirm the disease. Therefore, it is necessary to review and obtain clinical information and echocardiographic image data of as many confirmed patients as possible. This study is a retrospective observational study, and the expected number of target subjects is about 500.

Description

Inclusion/exclusion criteria

1. Selection criteria for screening (1) 18 years old or older (2) Patients with infiltrative cardiomyopathy (the diagnostic name for each of the following diseases) or systemic disease (such as amyloidosis, multiple myeloma, sarcoidosis) (3) Search Period: January 1, 2010-December 31, 2020

2. Criteria for enrolling patients

   • Patients who are satisfied with at least one of each definition are selected.

     • Cardiac amyloidosis1,5,11,12 I. 'Definite': Positive myocardial biopsy (Congo-Red positive) II. 'Probable': One of the following imaging findings along with a positive biopsy of tissues other than myocardium A. Positive DPD / PYP scan Grade 2-3 cardiac uptake B. Echocardiography Symmetrical increase in LV and RV wall thickness Dilated LA and RA Granular appearance of myocardium Pericardial effusion Decreased or normal RQS complex voltage despite increased LV wall thickness C. Cardiac magnetic resonance imaging Diffuse subendocardial late Gd-enhancement Elevated native T1 and ECV value III. 'Possible': Two or more of the above imaging findings are satisfied without biopsy findings, and it is suitable for the diagnosis according to all clinical findings

       ② Cardiac sarcoidosis13,14,15,16 I. 'Definite': If all of the following are satisfied A. Noncaseating, multinucleated giant cell granuloma surrounded by bands of dense collagen fibers in endomyocardial biopsy B. Compatible clinical presentation C. Exclusion of other causes of granulomatous inflammation II. 'Probable': Two or more of the following findings along with a positive biopsy of tissues other than myocardium A. Electrocardiogram High-grade atrioventricular block (including complete atrioventricular block) or fatal ventricular arrhythmia (e.g., sustained ventricular tachycardia and ventricular fibrillation) B. Echocardiography Variable focal LV wall thinning (frequently at the basal septum, lateral wall) Focal wall motion abnormalities do not match coronary artery territory C. Cardiac magnetic resonance imaging Patch, basal and lateral LV wall late Gd-enhancement D. Positron Emission Tomography - Computed Tomography Focal increased FDG-uptake IV. 'Possible': Two or more of the above imaging findings are satisfied without biopsy findings, and it is suitable for the diagnosis according to all clinical findings

       • Hemochromatosis 17 I. 'Definite': Positive myocardial biopsy Iron deposits within the myocyte II. 'Probable': Non-myocardial tissue biopsy positive or iron overload clinical evidence (such as hereditary hemochromatosis, transfusion-dependent anemia) and the following imaging findings A. Echocardiography Dilated LV with global systolic dysfunction B. Cardiac magnetic resonance imaging Low T2* value of myocardium

   Etc

   ① Fabry disease18,19 I. 'Definite': Positive myocardial biopsy Enlarged myocytes with clusters of concentric glycolipid (myelinoid bodies) within lysosomes II. 'Probable': A-galactosidase A screening test and X-linked genetic test positive, along with the following echocardiographic findings A. Echocardiography Symmetrical increase in LV and RV wall thickness

   ② Danon disease20 I. 'Definite': Positive for genetic testing or biopsy of myocardial tissue, along with the following echocardiographic findings Symmetrical increase in LV and/or RV wall thickness Decreased LV systolic function

   ③ Cardiac oxalosis1 I. 'Definite': Positive myocardial biopsy II. 'Probable': The following echocardiographic findings along with a history of massive transfusion or positive biopsy of tissues other than myocardium Symmetrical increase in LV and RV wall thickness Patchy, echodense speckled reflection

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
infiltrative cardiomyopathy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sensitivity	Sensitivity (True Positive Rate) refers to the proportion of those who have the infiltrative cardiomyopathy that received a positive result on the diagnostic algorythm by machine learning.	until June 30, 2022
Specificity	Specificity refers to the proportion of those who do not have the infiltrative cardiomyopathy that received a negative result on the test.	until June 30, 2022
Area under the curve of the receiver operation characteristics		until June 30, 2022

Collaborators and Investigators

• Sponsor: Yonsei University
• Investigators: Principal Investigator: Hyuk-jae Chang, Yonsei University Health System, Severance Hospital, Division of Cardiology

Publications and helpful links

General Publications

• Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol. 2010 Apr 27;55(17):1769-79. doi: 10.1016/j.jacc.2009.12.040.
• van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, Beets-Tan RGH, Fillion-Robin JC, Pieper S, Aerts HJWL. Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Res. 2017 Nov 1;77(21):e104-e107. doi: 10.1158/0008-5472.CAN-17-0339.

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 4, 2021
• Primary Completion (ANTICIPATED): December 16, 2021
• Study Completion (ANTICIPATED): December 31, 2021

Study Registration Dates

• First Submitted: October 24, 2021
• First Submitted That Met QC Criteria: October 24, 2021
• First Posted (ACTUAL): November 4, 2021

Study Record Updates

• Last Update Posted (ACTUAL): November 4, 2021
• Last Update Submitted That Met QC Criteria: October 24, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Cardiomyopathies
• Other Study ID Numbers: 4-2020-1278

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No